Outcome of Board Meeting including Unaudited Financial Results for the quarter and Half Year ended September 30, 2025 and other matters as approved by the Board
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Relic Technologies' Board approved unaudited results for Q2 and H1 FY26 on November 8, 2025. On a standalone basis, revenue from operations was nil for both the quarter and half year, with the company relying entirely on other income of Rs 22.92 lakhs (Q2) and Rs 57.74 lakhs (H1). Standalone net profit stood at Rs 9.84 lakhs for the quarter and Rs 27.34 lakhs for H1 FY26, up sharply from Rs 3.74 lakhs a year ago, driven mainly by investment income. On a consolidated basis, revenue from operations grew to Rs 187.91 lakhs (H1 FY26) from Rs 103.90 lakhs (H1 FY25), but the company reported a net loss of Rs 353.12 lakhs due to a Rs 232.12 lakh goodwill amortization (exceptional item) from its recently acquired subsidiary Truhealthy Wellness. Auditor D. Kothary & Co. issued an unmodified (clean) review report. The Board also approved voluntary strike-off of non-operational subsidiary Relic Pharma Limited, to be completed by March 31, 2026.
Positive on standalone side (higher other income boosting profits) but the consolidated picture is weak with a large goodwill impairment and net loss. Standalone core operations are essentially stalled with no revenue from operations, so profitability depends on treasury gains. The strike-off of a non-operative subsidiary is housekeeping and unlikely to affect share price. Existing shareholders should note the negative consolidated operating cash flow (~Rs 377 lakhs) and rising consolidated borrowings.